High Dose Chemotherapy with Stem Cell Support for Solid Tumours
Author Information
Author(s): Porrata L F, Adjei A A
Primary Institution: Mayo Clinic
Hypothesis
The study investigates the effectiveness of high dose chemotherapy with haematopoietic stem cell support based on the dose-response relationship of chemotherapeutic agents.
Conclusion
Only a few chemotherapeutic agents showed a steep dose-response relationship, indicating limited pharmacologic evidence for others in high dose chemotherapy for solid tumours.
Supporting Evidence
- Only BCNU, melphalan, nitrogen mustard, and the combination of thiotepa and cyclophosphamide demonstrated steep dose-response relationships.
- The pharmacologic evidence for the use of other antineoplastic agents for HDT in solid tumours is non-existent.
- More preclinical studies are needed for a rational development of this therapeutic approach.
Takeaway
This study looks at how some cancer treatments work better at higher doses, but only a few medicines are proven to do this well.
Methodology
The study reviews preclinical pharmacologic studies and literature from 1966 to 1999.
Limitations
The evidence for many antineoplastic agents is lacking, and more studies are needed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website